Long-Term Remission after Autologous Stem-Cell Transplantation for Relapsed Histiocytic Sarcoma

Abusanad, Atlal; Warsi, Ashraf; Michel, René P.; Nahal, Ayoub; Popradi, Gizelle; Storring, John M.; Liberman, A S; Alcindor, Thierry

doi:10.3747/co.19.964

Cited by 12 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Induction is usually followed by consolidation with combinations of cyclophosphamide, cytarabine, vincristine, PEG-asparaginase, and 6-mercaptopurine, 16 or cyclophosphamide and actinomycin-D, or idarubicin and cladribine. 15 Refractory disease has been treated with autologous hematopoietic stem-cell transplantation 17 followed by thalidomide 18 and alemtuzumab 13 for refractory disease, and BRAF inhibitors such as vemurafenib for HS with BRAF V600E mutations. 19 Both surgery 12,14,20 and radiotherapy 11…”

Section: Ta B L E 1 Therapeutic Pathwaymentioning

confidence: 99%

Histiocytic sarcoma in a child—successful management and long‐term survival with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Sandler

Franklin

Hayes‐Jordan

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Histiocytic sarcoma is an extremely rare tumor in children. It may occur sporadically or in association with other hematological malignancies. It arises most commonly in the lymph nodes but may occur anywhere in the body and clinical presentation is usually with advanced disease. Following tissue diagnosis and staging, management is with chemotherapy though there are no standard regimes. Surgery has been used successfully for local control. This is the first description of the use of peritonectomy and hyperthermic intraperitoneal chemotherapy to treat histiocytic sarcoma. The 4-year-old patient has been disease free for 6 years.

show abstract

Section: Ta B L E 1 Therapeutic Pathwaymentioning

confidence: 99%

Histiocytic sarcoma in a child—successful management and long‐term survival with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Sandler

Franklin

Hayes‐Jordan

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Novel approaches in using treatments such as thalidomide , alemtuzumab , and vemurafenib have also been tried in few individual cases with good therapeutic responses. Allo‐SCT is mainly reserved for relapsed HS and few cases with complete response have been documented . Myeloablative allo‐SCT with cyclophosphamide/TBI conditioning yielded a complete response in a patient after induction chemotherapy with CLAG‐M regimen and bridging with vinblastine .…”

Section: Reprogramming Via Epigenetic Influencesmentioning

confidence: 99%

Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment

Ansari

Naqash

Munker

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is an extremely rare non-Langerhans cell disorder with an aggressive course and limited treatment options. Recent advances in molecular/genetic sequencing have suggested a common clonal origin between various hematolymphoid disorders and cases of secondary HS. Deriving conclusions from previously reported cases of HS arising secondarily to certain hematolymphoid disorders, here we have tried to provide insight into the mechanisms influencing this evolution. We also discuss a clinical case of a 72-year-old man with a diagnosis of chronic myeloid leukemia (CML), presenting subsequently with a heterogeneous liver mass positive with a diagnosis of HS. The liver mass showed a retained BCR-ABL1 translocation suggesting clonality between the CML and HS. As seen in our case and other reported cases of HS derived secondarily, the concurrent expression of immunoglobulin heavy (IGH)-/lightchain rearrangements or cytogenetic markers common to the primary malignancy suggests an evolutionary mechanism involving lineage switching that could potentially be influenced by genetic or epigenetic cues which may occur at the level of a progenitor or the malignant cell itself. Clinical caseA 72-year-old male was brought to the emergency room with a one-month history of progressively worsening bilateral lower extremity swelling, more than 10 lbs. of weight loss, lack of appetite, and rapidly declining performance status. His past medical history was notable for CML, which was diagnosed 30 months prior to presentation (Fig. 1). The patient was treated on a protocol with imatinib (400 mg daily) and demonstrated a complete molecular response to tyrosine kinase inhibitor (TKI) therapy. Focused physical examination demonstrated an emaciated male in mild distress from abdominal pain, right upper quadrant tenderness on deep palpation, and abdominal distension without any signs of an acute abdomen.His peripheral blood smear revealed normochromic, normocytic anemia with hemoglobin of 7.6 g/dL (normal range, 12.5-16.3 g/dL), a white blood count of 7 730/lL (normal range, 3 600-11 200/lL), a red blood cell count of 2.78 M/lL (normal range 4.06-5.63 M/lL), and a platelet count of 114 000/lL (normal range, 159 000-386 000/lL). Serum iron was low (21 lg/dL) with a low TIBC (216 lg/dL), which was attributed to anemia of chronic disease. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis revealed the absence of the BCR/ABL transcript in the peripheral blood.Computed tomography scan of the chest and abdomen revealed a large, complex, heterogeneous, hypodense mass involving nearly all of the caudate and left lobes of the liver. These lesions were not present in the previous examination carried out 1 year before.Biopsy of the liver mass revealed diffuse infiltration of large and irregular pleomorphic cells with lobulated nuclei with some binucleated and trinucleated cells containing

show abstract

“…The experimental use of thalidomide, alone or in combination with imatinib, bevacizumab, or sorafenib, respectively, has also been effective in individual cases [2,20,182]. Other groups have reported on high-dose chemotherapy with autologous or allogeneic stem cell transplantation [4,182].…”

Section: Therapymentioning

confidence: 99%

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

Rare histiocytoses, also called non-Langerhans cell histiocytoses, include all proliferative disorders of histiocytes, macrophages and dendritic cells that are not classified as Langerhans cell histiocytosis (LCH) and do not belong to the hemophagocytic lymphohistiocytosis (HLH) group of diseases. Thus, the term includes numerous benign or malignant, localized or systemic, adult or pediatric diseases. The classification of the histiocytic disorders has been revised several times. Here, we follow the classification recently published by Jean Francois Emile and an international expert panel, defining subgroups of histiocytoses described as L-Group, C-Group, M-Group, R-Group, and H-Group, which stands for LCH-like, cutaneous or mucocutaneous, malignant, Rosai-Dorfman-Disease like and HLH like. Some of the diseases have an excellent prognosis after resection or even disappear spontanously, others progress rapidly, requiring intensive systemic therapies. The malignant non-Langerhans cell histiocytoses in general have a poor prognosis, here, complex chemotherapy protocols are usually applied, with inconsistant results. An interesting perspective in non-malignant rare histiocytoses might be small molecular inhibitors, in particular BRAF inhibitors, since BRAF mutations have been found in some subtypes of non-Langerhans cell histiocytoses. By prospective and retrospective collection of experiences in a new registry (the "International Rare Histiocytic Disorders Registry", IRHDR), knowledge about these rare diseases might hopefully be improved.

show abstract

Long-Term Remission after Autologous Stem-Cell Transplantation for Relapsed Histiocytic Sarcoma

Cited by 12 publications

References 7 publications

Histiocytic sarcoma in a child—successful management and long‐term survival with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Histiocytic sarcoma in a child—successful management and long‐term survival with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

Contact Info

Product

Resources

About